Shook J E, Lemcke P K, Gehrig C A, Hruby V J, Burks T F
Department of Pharmacology, University of Arizona Health Sciences Center, Tucson.
J Pharmacol Exp Ther. 1989 Apr;249(1):83-90.
We evaluated the ability of mu [morphine, Tyr-Pro-N-MePhe-D-Pro-NH2 (PLO17)], delta (Tyr-D-Pen-Gly-Phe-D-Pen) (DPDPE) and kappa [U50,488H, (trans-3,4-dichloro-N-methyl-N-(2-(1-pyr-rolidinyl) cyclo-hexyl)benzeneacetamine)] opioid receptor selective agonists to inhibit diarrhea induced by castor oil (0.6 ml p.o.) in mice after supraspinal (i.c.v.) and peripheral (s.c.) administration. The antidiarrheal potency of each compound was compared to its analgesic and gastrointestinal antitransit potency when given by the same route of administration. When administered i.c.v., morphine, PLO17 and DPDPE inhibited diarrhea in a dose-related fashion. The mu agonists, morphine and PLO17, given i.c.v, inhibited diarrhea at doses much lower than those needed to produce analgesia or to inhibit gastrointestinal transit. DPDPE (i.c.v.) was equipotent in inhibiting diarrhea and in eliciting analgesia, but did not effect the rate of transit. U50,488H (i.c.v.) inhibited diarrhea only at extremely high doses which also caused profound postural-motor incapacitance. U50,488H given i.c.v. had no effect on transit at any dose. When given peripherally, morphine, PLO17, DPDPE and U50,488H all inhibited diarrhea in a dose-related fashion. All four compounds inhibited diarrhea at doses much below those needed to cause analgesia. Morphine s.c. and PLO17 s.c. both inhibited diarrhea at doses lower than those required to inhibit transit. DPDPE s.c. and U50,488H s.c. had no effect on transit at any dose. The antidiarrheal effects of i.c.v. morphine, i.c.v. PLO17 and i.c.v. DPDPE were antagonized by pretreatment with 1 microgram i.c.v. of naltrexone.(ABSTRACT TRUNCATED AT 250 WORDS)
我们评估了μ[吗啡,酪氨酰-脯氨酰-N-甲基苯丙氨酰-D-脯氨酰胺(PLO17)]、δ[酪氨酰-D-青霉胺-甘氨酰-苯丙氨酰-D-青霉胺(DPDPE)]和κ[U50,488H,(反式-3,4-二氯-N-甲基-N-(2-(1-吡咯烷基)环己基)苯乙酰胺)]阿片受体选择性激动剂在脊髓上(脑室内)和外周(皮下)给药后抑制蓖麻油(0.6毫升,口服)诱导的小鼠腹泻的能力。将每种化合物的止泻效力与其通过相同给药途径给药时的镇痛和胃肠道抗转运效力进行比较。脑室内给药时,吗啡、PLO17和DPDPE以剂量相关方式抑制腹泻。脑室内给予μ激动剂吗啡和PLO17时,抑制腹泻的剂量远低于产生镇痛或抑制胃肠道转运所需的剂量。DPDPE(脑室内)在抑制腹泻和引发镇痛方面效力相当,但不影响转运速率。U50,488H(脑室内)仅在极高剂量下抑制腹泻,而该剂量也会导致严重的姿势运动无能。脑室内给予U50,488H在任何剂量下均对转运无影响。外周给药时,吗啡、PLO17、DPDPE和U50,488H均以剂量相关方式抑制腹泻。所有四种化合物抑制腹泻的剂量远低于引起镇痛所需的剂量。皮下注射吗啡和皮下注射PLO17均在低于抑制转运所需的剂量下抑制腹泻。皮下注射DPDPE和皮下注射U50,488H在任何剂量下均对转运无影响。脑室内注射吗啡、脑室内注射PLO17和脑室内注射DPDPE的止泻作用可被脑室内预先注射1微克纳曲酮拮抗。(摘要截断于250字)